KEGG   DRUG: Doravirine and islatravir
Entry
D13246            Mixture   Drug                                   
Name
Doravirine and islatravir;
Idvynso (TN)
Product
IDVYNSO (Merck Sharp & Dohme LLC)
Component
Doravirine [DR:D10624], (Islatravir hydrate [DR:D11914] | Islatravir [DR:D11432])
Class
Antiviral
 DG03107  Anti-HIV agent
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
Remark
Therapeutic category: 6250
Product: D13246<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Doravirine is primarily metabolized by CYP3A.
Target
HIV-1 reverse transcriptase [KO:K24802]
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551]
Interaction
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D13246  Doravirine and islatravir
Drug groups [BR:br08330]
 Antiviral
  DG03107  Anti-HIV agent
   D13246  Doravirine and islatravir
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   D13246  Doravirine and islatravir
Antimicrobials [BR:br08307]
 Antivirals
  Genome replication inhibitor
   HIV reverse transcriptase inhibitor
    D13246  Doravirine and islatravir <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D13246
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D13246
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D13246
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D13246
Other DBs
PubChem: 527701149
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system